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Edited by Veli-Pekka LehtoAbstract Podoplanin/aggrus is increased in tumors and its
expression was associated with tumor malignancy. Podoplanin
on cancer cells serves as a platelet-aggregating factor, which is
associated with the metastatic potential. However, regulators
of podoplanin remain to be determined. Transforming growth
factor-b (TGF-b) regulates many physiological events, including
tumorigenesis. Here, we found that TGF-b induced podoplanin in
human ﬁbrosarcoma HT1080 cells and enhanced the platelet-
aggregating-ability of HT1080. TGF-b type I receptor inhibitor
(SB431542) and short hairpin RNAs for Smad4 inhibited the
podoplanin induction by TGF-b. These results suggest that
TGF-b is a physiological regulator of podoplanin in tumor cells.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
Keywords: Podoplanin; Platelet aggregation; TGF-b; Smad;
Fibrosarcoma1. Introduction
A mucin-type transmembrane sialoglycoprotein, podoplanin
(aggrus) is highly expressed in lymphatic endothelial cells
(LECs) [1]. Several lines of evidence obtained using podopla-
nin knockout mice suggest that podoplanin is crucially in-
volved in lymphatic vessel formation [2]. Moreover,
podoplanin is reportedly expressed in several tumor cells such
as various squamous cell carcinomas, testicular tumors, meso-
thelioma, and brain tumors, although podoplanin is not ex-
pressed in gastrointestinal and pulmonary adenocarcinomas,
which frequently undergo metastasis [3]. Recent investigations
have reinforced the notion that expression of podoplanin is
associated with tumor malignant progression [4].
Podoplanin belongs to the family of type-I transmembrane
sialomucin-like glycoproteins and possess the platelet-aggregat-
ing activity and metastasis-promoting ability [5,6]. The segmentAbbreviations: PLAG, platelet-aggregation-stimulating; TGF-b, trans-
forming growth factor-b; R-Smad, receptor-regulated Smad; IL,
interleukin; EMT, epithelial–mesenchymal transition
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platelet-aggregation-stimulating (PLAG) domain, is critical
for the activity of podoplanin. In particular, this motif, which
is highly conserved across species, is triplicated in tandem [7].
In a study of targeted mutagenesis of podoplanin molecules,
we obtained evidence that Thr residues in the PLAG domain
play an important role in platelet aggregation [5]. Recently, we
puriﬁed human podoplanin from the glioblastoma cell line
LN319 cells using an anti-human PLAG domain monoclonal
antibody (NZ-1), and showed that podoplanin possesses a
disialyl-core1 structure at Thr52 in the PLAG domain [8]. Fur-
thermore, C-type lectin-like receptor 2 (CLEC-2), which is a
non-classical C-type lectin, was identiﬁed as an endogenous
receptor of podoplanin on platelet [9]. NZ-1 neutralized the
association between podoplanin and CLEC-2, and suppressed
podoplanin-induced platelet aggregation and metastasis [10].
Transforming growth factor-b (TGF-b) superfamily of
extracellular growth factors regulates cell proliferation, diﬀer-
entiation, apoptosis, and morphogenesis. Upon ligand binding
to two diﬀerent types of serine/threonine kinase receptors, type
I receptor is activated by type II receptor and transduces intra-
cellular signals by phosphorylation of receptor-regulated Smad
(R-Smad). Among R-Smad, Smad1, Smad5, and Smad8 are
phosphorylated by the bone morphogenetic protein (BMP)
receptors, whereas Smad2 and Smad3 are phosphorylated by
the TGF-b/activin receptors [11]. Phosphorylated R-Smad
forms a functional signaling complex with Smad4 and translo-
cates into the nucleus to regulate expression of the ligand-
responsive genes [12]. TGF-b regulates a number of genes in
a cell type and context dependent manner.
Podoplanin has been reported to be expressed in invading
front of tumors cells and be involved in tumor invasion [13];
therefore, some stromal factors might be involved in the induc-
tion of podoplanin. Previously, Interkeukin-3 (IL-3) was re-
ported to induce podoplanin in human endothelial cells [14].
However, it has not been clariﬁed how the expression of podopl-
anin is regulated in tumor cells. In this study, we examined the
expression of podoplanin by TGF-b using various cell lines.2. Materials and methods
2.1. Cells and reagents
HT1080, 293T, HaCaT, and MCF10A cells were obtained from the
American Type Culture Collection (ATCC). These cells were cultured
in Dulbeccos modiﬁed Eagles medium (Sigma, St. Louis, MO)blished by Elsevier B.V. All rights reserved.
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lin–streptomycin solution (Invitrogen Corp., Carlsbad, CA). Puromy-
cin and SB431542 was obtained from Sigma and Calbiochem
Novabiochem Corp. (San Diego, CA), respectively. TGF-b was pur-
chased from R&D Systems (Minneapolis, MN).2.2. DNA constructs
Sequence of oligonucleotides against human Smad4 cDNA was as
follows: GGATTTCCTCATGTGATCT. The complementary oligo-
nucleotides were annealed and ligated in a pSUPER. puro vector (Oli-
goEngine, Seattle, WA). Stable HT1080 clones transfected with
pSUPER-short hairpin RNAs for Smad4 (shSmad4) were selected
and maintained in the presence of puromycin (1 lg/ml).
2.3. Reverse transcription (RT)-PCR
Total RNA was prepared using Isogen (Nippongene Co. Ltd., To-
kyo, Japan). Reverse transcription was performed with Superscript
III (Invitrogen Corp.), and PCR was performed using the primers
listed as follows: podoplanin – 5 0-CCAGGAGAGCAACAACTCA
A-3 0 (forward), 5 0-GATGCGAATGCCTGTTACAC-30 (reverse);
Smad7 – 5 0-GGAAGTCAAGAGGCTGTGTT-30 (forward), 5 0-GCT
TTCTCCTCCCAGTATGC-3 0 (reverse); b-actin – 5 0-CAAGAGAT
GGCCACGGCTGCT-3 0 (forward), 5 0-TCCTTCTGCATCCTGTC
GGCA-3 0 (reverse).
2.4. Luciferase assay
Cells were transfected with (CAGA)9 MLP-luc using FuGENE6
(Roche Diagnostics K.K., Tokyo, Japan). Luciferase activities were
determined by Luciferase Assay Systems (Promega K.K., Tokyo, Ja-
pan) and normalized to b-galactosidase activity of co-transfected
CH110 (GE Healthcare UK Ltd., Buckinghamshire, UK).
2.5. Flow cytometry
Expression levels of human podoplanin were compared for conﬁrma-
tionusingﬂowcytometry.HT1080 cells, whichwere collectedby trypsin-
EDTA treatment, were incubated with NZ-1 (0.1 lg/ml) for 1 h at 4 C.
Then the cells were incubated with Oregon green-conjugated anti-rat
antibodies (Invitrogen Corp.) for 30 min. Flow cytometry was per-
formed using FACS Caliber (BD Biosciences, Barintree, MA).2.6. Western blot analysis
The cell lines were solubilized with lysis buﬀer (1% Triton in PBS)
and electrophoresed under reducing conditions on 10–20% polyacryl-
amide gels. The separated proteins were transferred to a PVDF mem-
brane. After blocking with 4% skim milk in PBS, the membrane was
incubated with NZ-1 (rat, 0.1 lg/ml), anti-Smad2 (mouse, 0.25 lg/
ml; Transduction Laboratories, Lexington, KY), anti-Smad4 (mouse,
0.2 lg/ml; Santa Cruz Biotechnology Inc., Santa Cruz, CA), anti-phos-
pho-Smad2 (rabbit) [15], and anti-b-actin antibody (mouse, 0.2 lg/ml;
Sigma), and then with peroxidase-conjugated anti-rat, anti-mouse, or
anti-rabbit antibodies (1/1000 diluted; GE Healthcare UK Ltd.), and
developed for 1 min with ECL reagents (GE Healthcare UK Ltd.)
using Kodak X-Omat AR ﬁlm.2.7. Platelet aggregation assay by WBA Carna
Heparinized human whole blood (WB) was drawn from healthy
drug-free volunteers. Platelet aggregation was measured according to
the screen ﬁltration pressure method using WBA Carna (IMI, Saitama,
Japan) [3,8,10]. Two hundred microliters each of human whole blood
samples in four reaction tubes were stirred at 1000 rpm at 37 C and
pre-incubated for 1 min, followed by addition of 10 ll each of
HT1080 cells (1 · 105 cells or 4 · 104). Using a 3.7-mm-diameter syr-
inge containing screen microsieves made of nickel, with 300 openings
of 20 · 20 lm2 in a 1 mm-diameter area, WB samples were sucked to
detect aggregation pressure at a rate of 200 ll/6.4 s 2 min later. The ﬁ-
nal platelet aggregation pressure of each reaction tube was determined
at the pressure rate (%) of a pressure sensor connected to the syringe.2.8. Statistical analyses
Results are expressed as the means ± S.D. Students t-test was used
to determine signiﬁcance among the groups. A value of p < 0.05 was
considered signiﬁcant.3. Results and discussion
3.1. Induction of podoplanin by TGF-b in hunan ﬁbrosarcoma
HT1080 cells
To examine the expression of podoplanin by TGF-b, we per-
formed Western blot analysis using anti-podoplanin monoclo-
nal antibody, NZ-1 [3] in various cell lines. As shown in
Fig. 1A, TGF-b induced podoplanin in human ﬁbrosarcoma
HT1080 cells, but not in breast epithelial MCF-10A cells and
human keratinocyte, HaCaT cells, which are known to exhibit
the high responsiveness to TGF-b. Although human embry-
onic kidney 293T cells express low level of podoplanin, the
induction of podoplanin by TGF-b was hardly observed. Time
course experiment showed that podoplanin mRNA increased
at 12 h treatment with TGF-b (Fig. 1B), followed by the
podoplanin protein at 24 h (Fig. 1C). Induction of Smad7
which is a target gene of TGF-b signaling, were observed in
HT1080 cells, indicating that TGF-b-Smad signaling pathway
is intact in HT1080 cells (Fig. 1B). Phosphorylation of Smad2
by TGF-b was also detected (Fig. 1C). Furthermore, we found
that SB431542, a selective inhibitor of TGF-b type I receptor,
inhibited the induction of podoplanin by TGF-b in a dose
dependent manner (Fig. 1D). These results indicated that
TGF-b stimulates podoplanin expression in HT1080 cells.
TGF-b is a potent growth inhibitor with tumor-suppressing
activity. Cancer cells often show resistance to this growth inhi-
bition either because of genetic loss of TGF-b signaling com-
ponents or, more commonly, because of downstream
perturbation of the signaling pathway, such as by Ras activa-
tion [16]. Carcinomas often secrete excess TGF-b and respond
to it by enhanced invasion and metastasis [17]. TGF-b is
known to induce epithelial–mesenchymal transition (EMT)
through the induction of SIP1 and d EF1 [18], Snail family
transcriptional factors [19], and the suppression of inhibitor
of DNA binding (Id) proteins [20]. Furthermore, TGF-b pro-
motes bone metastasis through the induction of IL-11 and con-
nective tissue growth factor [21]. Podoplanin has been also
reported to induce EMT in MDCK cells linked to the activa-
tion of RhoA, and increased cell migration and invasiveness
[13]. Although TGF-b induces podoplanin in HT1080 cells,
it is not suﬃcient to induce the invasion and migration of
HT1080 cells [22]. Even though, podoplanin might be one of
cancer progressive factor, which is regulated by TGF-b.3.2. Platelet aggregation by HT1080 cells
To conﬁrm the expression of functional podoplanin on cell
surface, we performed the ﬂow cytometry using anti-podopla-
nin (NZ-1). As shown in Fig. 2A, the expression of podoplanin
on cell surface was observed in the absence of TGF-b and its
expression was further stimulated by TGF-b. We next investi-
gated the platelet aggregation by HT1080 cells in the presence
or absence of TGF-b. Platelet aggregation was observed in
control HT1080 cells, and was further stimulated by TGF-b-
treated HT1080 cells (Fig. 2B). These results suggest that func-
tional podoplanin was induced on cell surface of HT1080 cells.3.3. Eﬀect of Smad4 knockdown on the induction of podoplanin
by TGF-b
We next investigated the involvement of Smad pathway on
the expression of podoplanin by TGF-b. We established
HT1080 cells which stably expressed short hairpin RNAs for
Fig. 1. Induction of podoplanin by TGF-b in human ﬁbrosarcoma HT1080 cells. (A) HaCaT, 293T, HT1080, and MCF10A cells were treated with
TGF-b (2.5 ng/ml) for 24 h. Western blot analysis was performed using anti-podoplanin antibody (NZ-1). The b-actin protein is used as a loading
control. (B and C) HT1080 cells were treated with TGF-b for indicated time periods. (B) Semi-quantitative RT-PCR analysis was performed to detect
podoplanin and Smad7 mRNA. b-actin is used as internal control. (C) Western blot analysis was performed using NZ-1, anti-phospho-Smad2, anti-
Smad2, and anti-b-actin antibodies. (D) HT1080 cells were treated with TGF-b in the presence or absence of SB431542 at indicated concentrations
for 24 h. Western blot analysis was performed using antibodies as indicated. D indicates dimethyl sulfoxide (solvent).
Fig. 2. Cell surface expression of podoplanin and platelet aggregation
by HT1080 cells. (A) Flow cytometric analyses of NZ-1 to HT1080
cells which were treated with TGF-b for 24 h. (B) Platelet aggregation
was measured using WBA Carna with the screen ﬁltration pressure
method. Data are means ± S.D. of three independent experiments.
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and 10), and these Smad4 were signiﬁcantly reduced compared
with control (pSUPER) transfected cells (Fig. 3A). However,
the expression of Smad2 and phosphorylation of Smad2 by
TGF-b were similar between control and shSmad4 transfected
cells. The transcriptional activation of (CAGA)9 MLP-luc by
TGF-b was signiﬁcantly reduced in shSmad4 transfected cells
(Fig. 3B). Using these transfectants, we investigated the induc-
tion of podoplanin by TGF-b. As shown in Fig. 3C, the induc-
tion of podoplanin by TGF-b was blocked in shSmad4
transfected cells. These results suggest that TGF-b-Smad path-
way is important for the induction of podoplanin by TGF-b in
HT1080 cells.
TGF-b regulates various target genes via Smad pathway
[23]. However, podoplanin was not induced by TGF-b in Ha-
CaT and MCF10A cells (Fig. 1A), which suggested that TGF-
b-Smad signaling alone is not suﬃcient to induce podoplanin.
Therefore, Smad would cooperatively regulate podoplanin
with other transcriptional factors, which maintain the basal
expression of podoplanin in HT1080 cells. Recent report re-
vealed that transcriptional factor Sp1 and Sp3 stimulate basal
podoplanin expression, and methylation status of its promoter
confers cell-type speciﬁc podoplanin expression [24]. Smads
have been shown to interact with Sp1, and regulates various
target genes including p21 [25]. Further study is needed to
identify the transcriptional factors which regulate podoplanin
with Smads.
In conclusion, we found that TGF-b induced podoplanin in
human ﬁbrosarcoma HT1080 cells. The platelet aggregation
by HT1080 cells was stimulated by treatment of cells with
TGF-b, which may lead to acquirement of high metastatic
ability of cancer cells. Furthermore, we are now investigating
whether podoplanin is induced by TGF-b in other cancer cells.
Fig. 3. Eﬀect of Smad4 knockdown on the TGF-b-induced podopl-
anin expression. (A) Western blot analysis of Smad4 in shSmad4-
transfected HT1080 cells (clones 5 and 10). Cells were treated with
TGF-b for 1 h. Western blot analysis was performed using anti-
Smad4, anti-phospho-Smad2, anti-Smad2, and anti-b-actin antibodies.
(B) (CAGA)9 MLP-luc activation by TGF-b was inhibited in
shSmad4-transfected cells. Cells were transfected with (CAGA)9
MLP-luc for 24 h and treated with TGF-b for another 24 h. Luciferase
activity was determined as described in Section 2. Error bars represent
means ± S.D. (C) Eﬀect of Smad4 knockdown on the TGF-b-induced
podoplanin expression. Cells were treated with TGF-b for 24 h.
Western blot analysis was performed using NZ-1 and anti-b-actin
antibodies.
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ising therapeutic target in cancer invasion and metastasis.
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